Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of December 2024, specifically dated December 5, 2024. The report serves to disseminate a press release regarding interim clinical study results for the Company's ProSense cryoablation system.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on clinical developments rather than a financial statement.
Material Changes and Clinical Results
The primary material update is the announcement of interim results from the ICESECRET study. The study evaluated the safety and effectiveness of IceCure's ProSense cryoablation system in the destruction of kidney tumors. Key findings include:
- Recurrence-Free Rate: 88.7% based on interim data.
- Indication: Destruction of kidney tumors.
- System: ProSense cryoablation system.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" section from the attached press release (Exhibit 99.1). The document does not contain specific numerical guidance, management commentary on financial outlook, or detailed risk factors within the body of the Form 6-K itself, deferring to the incorporated press release for such disclosures.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed study methodology and patient demographics.
- Review the "Forward Looking Statements" section in the press release for specific risks associated with the clinical data.
- Confirm the timeline for final study results and potential regulatory submission plans.
- Check subsequent filings for any updates on the commercial impact of these clinical results.